Abstract Number: 46 • Pediatric Rheumatology Symposium 2017
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
Background/Purpose: Enthesitis-related arthritis (ERA) is a JIA category primarily affecting entheses and peripheral joints but can involve the axial skeleton. Disease activity and structural change…Abstract Number: 45 • Pediatric Rheumatology Symposium 2017
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…Abstract Number: 1477 • ACR/ARHP Annual Meeting 2015
Patterns of Enthesitis and Arthritis in Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses a heterogeneous group of diseases characterized by chronic joint inflammation with presence of enthesitis as an important classification criteria.…
